NASDAQ · OCGN
Healthcare · Biotechnology
$1.06
Up+$0.03 (+2.91%)
Updated Sep 19, 2026, 12:38 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OCGN closed at $1.06 after 20 trading sessions, down 23.74% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $1.025 | $1.085 | $1.00 | $1.06 | 14.76M |
| Sep 17, 2026 | $1.02 | $1.06 | $1.01 | $1.03 | 3.91M |
| Sep 16, 2026 | $0.997 | $1.015 | $0.97 | $0.9984 | 9.09M |
| Sep 15, 2026 | $1.05 | $1.06 | $0.98 | $0.9935 | 12.65M |
| Sep 14, 2026 | $1.035 | $1.07 | $1.00 | $1.06 | 6.68M |
| Sep 11, 2026 | $1.04 | $1.06 | $1.01 | $1.02 | 6.47M |
| Sep 10, 2026 | $1.095 | $1.095 | $1.01 | $1.025 | 22.25M |
| Sep 9, 2026 | $1.31 | $1.3197 | $1.06 | $1.065 | 39.26M |
| Sep 8, 2026 | $1.35 | $1.36 | $1.32 | $1.33 | 2.82M |
| Sep 4, 2026 | $1.32 | $1.38 | $1.31 | $1.36 | 3.57M |
| Sep 3, 2026 | $1.335 | $1.35 | $1.30 | $1.35 | 2.42M |
| Sep 2, 2026 | $1.34 | $1.38 | $1.31 | $1.32 | 4.28M |
| Sep 1, 2026 | $1.33 | $1.34 | $1.29 | $1.33 | 2.18M |
| Aug 31, 2026 | $1.315 | $1.34 | $1.28 | $1.33 | 4.66M |
| Aug 28, 2026 | $1.37 | $1.37 | $1.32 | $1.32 | 3.1M |
| Aug 27, 2026 | $1.42 | $1.42 | $1.36 | $1.37 | 2.9M |
| Aug 26, 2026 | $1.405 | $1.42 | $1.38 | $1.41 | 2.01M |
| Aug 25, 2026 | $1.39 | $1.43 | $1.38 | $1.40 | 4.59M |
| Aug 24, 2026 | $1.41 | $1.41 | $1.33 | $1.36 | 2.89M |
| Aug 21, 2026 | $1.41 | $1.42 | $1.37 | $1.39 | 2.45M |
The latest Smart Investors Daily articles mentioning OCGN.
OCGN research
Company profile and research snapshot.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 27, 2026 | Canaccord Genuity | Buy | — |
| Mar 25, 2026 | Chardan Capital | Buy | — |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 16, 2026
Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion. The company expects top-lin
SeekingAlpha · Sep 11, 2026
Ocugen is advancing three gene therapy programs targeting major unmet needs in ophthalmology. Click here to read more on why OCGN gets a Buy rating.
Benzinga · Sep 10, 2026
Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data.
Benzinga · Sep 10, 2026
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OCGN.
